Avodart Manufacturer Copay Program: How to Get Dutasteride Cheap in 2026

What Is the Avodart Manufacturer Copay Program and Is It Still Active?

GSK offered branded Avodart copay assistance cards for several years after the drug's 2001 FDA approval for benign prostatic hyperplasia (BPH). Those cards allowed commercially insured patients to pay as little as $10 to $25 per fill. Since generic dutasteride entered the U.S. Market in 2015, GSK has progressively wound down branded savings support. As of early 2026, the GSK Avodart savings card program is no longer broadly available to new enrollees.

Copay assistance programs change frequently. Before assuming any program is active or inactive, check directly at gsk.com or call GSK patient support at 1-888-825-5249.

Why the Program Was Scaled Back

Brand copay cards exist to keep commercially insured patients on a branded product instead of switching to a cheaper generic. Once generic dutasteride became widely available and priced well under $30 per month, maintaining a copay card program made little financial sense for GSK. The branded Avodart price at full retail can exceed $200 for 30 capsules, while the generic version of the same 0.5 mg dose costs pharmacies a fraction of that. The FDA's generic drug program explains how generic entry typically drives prices down by 80 to 85 percent within the first year of competition.

What to Do If You Still Want Branded Avodart

Patients specifically seeking branded Avodart (not generic) should:

1. Call GSK directly at 1-888-825-5249 to ask whether any current savings program exists for their situation.
2. Ask their prescribing physician whether branded Avodart offers any clinical advantage over generic dutasteride for their specific case. In most situations, it does not.
3. Check NeedyMeds.org and RxAssist.org for any patient assistance programs that may still apply.

How Much Does Dutasteride Cost Without Insurance in 2026?

Generic dutasteride 0.5 mg (30 capsules) averages approximately $25 cash-pay at GoodRx-participating pharmacies. Some warehouse clubs and discount pharmacies price it lower. The branded Avodart equivalent, if dispensed instead of the generic, can run $180 to $220 per month without insurance at retail pharmacies, based on current pharmacy benefit data.

Price Comparison by Source

| Source | Approximate Monthly Cost | |---|---| | Generic dutasteride (GoodRx coupon) | $10 to $30 | | Generic dutasteride (retail without coupon) | $40 to $80 | | Branded Avodart (retail without insurance) | $180 to $220 | | Compounded dutasteride (503A pharmacy) | $30 to $50 | | Mark Cuban Cost Plus Drugs | Check costplusdrugs.com for current listing |

Prices vary by zip code, pharmacy, and dispensing quantity. Buying a 90-day supply instead of 30 days frequently reduces the per-unit cost by 10 to 20 percent.

Using GoodRx and Similar Discount Programs

GoodRx, RxSaver, and SingleCare are pharmacy benefit intermediaries. They negotiate discounted rates with pharmacy chains and pass those discounts to patients as printable or digital coupons. These coupons are usable regardless of insurance status. According to the FDA's guidance on drug pricing transparency, these programs are legal and widely used.

Steps to use a discount coupon:

1. Search "dutasteride 0.5 mg" on GoodRx.com or the GoodRx app.
2. Select your nearest participating pharmacy.
3. Show the coupon at the pharmacy counter before the pharmacist rings the prescription.
4. Do not use insurance and the GoodRx coupon at the same time. Pick whichever is cheaper.

A 2019 analysis published in JAMA Internal Medicine found that GoodRx prices were lower than insurance copays for 23 percent of the 9 generic drugs studied, particularly for patients with high-deductible plans. Dutasteride is among the generic drugs where cash-pay pricing regularly beats insurance cost-sharing.

How Does Insurance Cover Dutasteride?

Most commercial health plans cover generic dutasteride for its FDA-approved indication, BPH. The Endocrine Society's 2010 clinical practice guideline on male hypogonadism and the American Urological Association (AUA) BPH guideline both recognize 5-alpha reductase inhibitors, including dutasteride, as first-line medical therapy for BPH in appropriate patients. Coverage for off-label uses, such as androgenetic alopecia (hair loss), is less consistent.

Formulary Tiers and Prior Authorization

Most commercial formularies place generic dutasteride on Tier 1 or Tier 2, meaning the copay is typically $5 to $40 per fill. Branded Avodart, if still dispensed, typically lands on Tier 3 or Tier 4, with copays ranging from $60 to $150 or more. A 2021 report from the Assistant Secretary for Planning and Evaluation (ASPE) at HHS noted that tiered formulary structures are the primary mechanism insurers use to steer patients toward lower-cost generics.

If your plan requires prior authorization for dutasteride, your prescribing physician will need to submit clinical documentation showing:

• Confirmed BPH diagnosis (International Prostate Symptom Score, or IPSS, typically required to be moderate to severe)
• Evidence of adequate prostate volume, usually 30 mL or greater on ultrasound or digital rectal exam
• Trial of alpha-blocker therapy if required by the plan's step-therapy policy

The FDA label for Avodart specifies the approved indication as "symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of BPH-related surgery." Quoting this language directly in a prior authorization appeal strengthens the case for coverage.

Medicare Part D Coverage

Under Medicare Part D, generic dutasteride is typically covered on the plan's formulary, though cost-sharing varies. During the deductible phase, a beneficiary may pay the full discounted cost, which is often $20 to $35 for a 30-day supply of the generic. Once the deductible is met, copays frequently drop to $0 to $10 for Tier 1 generics. The CMS Medicare Part D formulary guidance provides a searchable tool for finding what each plan charges.

Patients with low income may qualify for the Extra Help (Low Income Subsidy) program, which can reduce Part D cost-sharing to $1.50 to $4.50 per generic prescription in 2026. Apply through the Social Security Administration or a State Health Insurance Assistance Program (SHIP) counselor.

Medicaid Coverage

Medicaid covers dutasteride in most states for BPH, though some state programs require prior authorization or restrict coverage to patients who have failed alpha-blocker monotherapy first. Check your state's preferred drug list (PDL) through your state Medicaid agency website.

Compounded Dutasteride: A Lower-Cost Alternative

Compounded dutasteride is prepared by licensed 503A compounding pharmacies and is often prescribed for androgenetic alopecia (hair loss) at doses and formulations not available commercially, such as topical dutasteride solutions or lower oral doses. Monthly costs for compounded dutasteride average approximately $40, compared with the branded Avodart retail price of $180 to $220.

When Compounding Makes Clinical Sense

The FDA's policy on compounding permits licensed pharmacies to prepare compounded drugs when a commercially available product does not meet a patient's specific medical need. Compounded dutasteride is commonly used when:

• A prescriber wants a topical formulation (not commercially available)
• The patient needs a dose different from the standard 0.5 mg capsule
• The patient is enrolled in a telehealth program that works with a specific compounding pharmacy

Compounded drugs are not FDA-approved as finished drug products. The FDA compounding FAQ notes that compounded preparations "lack FDA approval for safety and efficacy," which patients should understand before switching from a commercially approved generic.

How to Verify a Compounding Pharmacy

Use only PCAB-accredited (Pharmacy Compounding Accreditation Board) or state-board-licensed 503A facilities. The National Association of Boards of Pharmacy (NABP) maintains a list of accredited compounding pharmacies. Never purchase compounded dutasteride from an unverified online pharmacy.

Dutasteride for Hair Loss: Access Considerations

Dutasteride is not FDA-approved for androgenetic alopecia in the United States, though it carries approval for that indication in South Korea and Japan. Off-label prescribing is legal for U.S. Physicians. A 2021 systematic review and meta-analysis in the Journal of the American Academy of Dermatology covering 7 randomized controlled trials found that dutasteride 0.5 mg produced significantly greater increases in hair count than finasteride 1 mg at 24 weeks (P<0.01), based on pooled data from 416 participants.

Because hair loss is an off-label indication, insurance coverage is rarely available. This makes the cash-pay generic at $25 per month or compounded topical preparations the most practical access paths for most patients using dutasteride for androgenetic alopecia.

The HealthRX Access Decision Framework for Dutasteride (Off-Label Hair Loss Use) follows three decision points. First, confirm clinical appropriateness with a licensed prescriber. Second, determine whether the patient has commercial insurance that might cover off-label use with a letter of medical necessity. Third, if no insurance coverage is available, route to generic dutasteride via GoodRx coupon (target price: under $30/month) or compounded topical dutasteride via a PCAB-accredited 503A pharmacy (target price: $30 to $50/month).

Dutasteride Clinical Background: Why Physicians Prescribe It

Dutasteride is a dual 5-alpha reductase inhibitor, blocking both type 1 and type 2 isoenzymes of 5-alpha reductase. This dual inhibition reduces serum dihydrotestosterone (DHT) by approximately 90 percent, compared with about 70 percent for finasteride, which inhibits only the type 2 isoenzyme. The FDA-approved prescribing information for Avodart documents this pharmacological distinction.

The CombAT Trial

The Combination of Avodart and Tamsulosin (CombAT) trial, a 4-year randomized controlled study in 4,844 men with BPH and enlarged prostates, found that combination therapy with dutasteride 0.5 mg plus tamsulosin 0.4 mg reduced the relative risk of acute urinary retention by 68 percent and BPH-related surgery by 71 percent compared with tamsulosin monotherapy. Results were published in European Urology in 2008. The trial is a primary evidence base for dutasteride's continued use in BPH management.

The REDUCE Trial

The Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial enrolled 6,729 men and found that dutasteride 0.5 mg daily over 4 years reduced the relative risk of biopsy-detectable prostate cancer by 22.8 percent compared with placebo (P<0.001). Results were published in The New England Journal of Medicine in 2010. This trial informed ongoing clinical discussions about dutasteride's role beyond symptomatic BPH, although the FDA did not approve dutasteride specifically for prostate cancer chemoprevention.

PSA Monitoring Requirement

Because dutasteride suppresses PSA (prostate-specific antigen) by approximately 50 percent after 6 months of use, clinicians must double the observed PSA value when interpreting results in patients on the drug. The American Cancer Society's prostate cancer screening guideline and the American Urological Association PSA guideline both note this adjustment requirement. Failure to apply the doubling correction can result in a falsely reassuring PSA and missed cancer detection.

Patient Assistance Programs Beyond the Manufacturer

When the branded manufacturer's copay program is unavailable and insurance does not cover a drug adequately, several other assistance pathways exist.

NeedyMeds and RxAssist

NeedyMeds and RxAssist maintain databases of pharmaceutical manufacturer patient assistance programs (PAPs). These programs typically serve uninsured or underinsured patients with income below 200 to 400 percent of the federal poverty level. As of 2026, no active GSK-sponsored PAP for dutasteride appears in these databases, but programs change, so checking directly is worthwhile.

State Pharmaceutical Assistance Programs (SPAPs)

Some U.S. States operate their own pharmaceutical assistance programs for seniors or low-income residents. The Medicare Rights Center maintains a state-by-state guide. Coverage of dutasteride under SPAPs depends on the state's formulary decisions.

340B Drug Pricing Program

Patients who receive care at federally qualified health centers (FQHCs), rural health clinics, or certain hospital outpatient departments may be eligible for medications at 340B prices. Under the 340B program, covered entities purchase drugs at significantly reduced prices and can pass those savings to eligible patients. For generic dutasteride, the 340B price may be negligible given the already-low cash price, but for patients needing branded Avodart, 340B savings could be meaningful.

Practical Step-by-Step Guide: Getting Dutasteride at the Lowest Cost

The following sequence applies to most patients as of 2026.

Step 1: Get the Prescription Written Correctly

Ask your prescriber to write "dutasteride 0.5 mg" and specifically indicate "substitution permitted" on the prescription. This allows the pharmacy to dispense the generic automatically. If the prescription says "Avodart" and "dispense as written" (DAW), the pharmacy must dispense branded Avodart at a much higher cost.

Step 2: Check Your Insurance Formulary

Log into your health plan's website or call the member services number on your insurance card. Search for "dutasteride" in the drug formulary tool. Note:

• The formulary tier (Tier 1 is cheapest)
• Whether prior authorization is required
• The copay or coinsurance amount during and after your deductible

If prior authorization is required, ask your prescriber's office to submit the paperwork. Most prior authorization decisions for medically appropriate BPH treatment are approved within 3 to 5 business days. The CMS guidance on Medicare prior authorization outlines timeframes and appeal rights.

Step 3: Compare GoodRx Against Your Insurance Copay

Even with insurance, your copay may exceed the cash-pay GoodRx price. Use GoodRx.com to check the price at pharmacies near you for generic dutasteride 0.5 mg. If the GoodRx price is lower than your copay, pay cash with the coupon. Remember: you cannot use both insurance and a GoodRx coupon on the same prescription fill, and using a coupon instead of insurance means the spend does not count toward your deductible.

Step 4: Consider a 90-Day Supply

Ask your prescriber to write a 90-day supply prescription. Most insurance plans and discount programs offer a lower per-unit cost for 90-day fills, and mail-order pharmacies frequently discount generics further. The NCPD (National Council for Prescription Drug Programs) sets the standards for how pharmacies process 90-day vs. 30-day claims, and most major pharmacy benefit managers (PBMs) honor 90-day generics at reduced cost-sharing.

Step 5: If Uninsured or Underinsured

Try these in order:

1. GoodRx coupon at a local pharmacy, targeting under $25 for 30 capsules.
2. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) for generic dutasteride if listed.
3. NeedyMeds or RxAssist for any active patient assistance program.
4. A PCAB-accredited compounding pharmacy if a non-standard formulation is clinically needed.
5. Federally qualified health center (FQHC) if income-eligible, for possible 340B pricing.

Safety and Monitoring: What Your Prescriber Should Review

Dutasteride carries a boxed FDA warning regarding fetal harm. The FDA prescribing information states: "Dutasteride capsules are not indicated for use in women or pediatric patients. Dutasteride is absorbed through the skin and could result in unintended fetal exposure. Women who are pregnant or may become pregnant should not handle dutasteride capsules."

Additional monitoring points:

• Baseline PSA before starting, then at 3 to 6 months, then annually. Double all PSA values for clinical interpretation.
• Liver function tests at baseline for patients with hepatic impairment, as dutasteride is extensively metabolized by CYP3A4.
• Sexual side effects, including decreased libido, erectile dysfunction, and ejaculation disorders, occur in approximately 3 to 5 percent of men in the first year per the REDUCE trial data. Most resolve with continued use.
• A 2011 FDA communication noted that 5-alpha reductase inhibitors may be associated with an increased risk of high-grade prostate cancer in men already at elevated risk. This does not apply to average-risk patients using the drug for BPH at recommended doses.

A 2020 population-based cohort study published in BMJ covering 120,928 men found no statistically significant increase in cardiovascular events among dutasteride users compared with finasteride users over a median 3.6-year follow-up. This is relevant for patients or prescribers concerned about cardiovascular safety differentiation between the two 5-alpha reductase inhibitors.